☆ 4.7 Article

Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

JOURNAL OF NUCLEAR MEDICINE (2010)

获取全文
添加到收藏夹

期刊

JOURNAL OF NUCLEAR MEDICINE
卷 51, 期 6, 页码 892-897

出版社

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.109.073239

关键词

diagnostic imaging; breast cancer; PET/CT; In-111; Ga-68

类别

Radiology, Nuclear Medicine & Medical Imaging

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

The clinical utility of a human epidermal growth factor receptor 2 (HER2)-targeting Affibody molecule for detection and characterization of HER2-positive lesions was investigated in patients with recurrent metastatic breast cancer. Methods: Three patients received In-111- or Ga-68-labeled DOTA(0)-Z(HER2:342-pep2) (ABY-002). gamma-Camera, SPECT, or PET/CT images were compared with earlier F-18-FDG PET/CT results. Results: Administration of radiolabeled ABY-002 was well tolerated. Blood kinetics of radiolabeled ABY-002 showed a first half-life of 4-14 min, second half-life of 1-4 h, and third half-life of 12-18 h. Radiolabeled ABY-002 detected 9 of 11 F-18-FDG-positive metastases as early as 2-3 h after injection. Conclusion: Molecular imaging using In-111-or Ga-68-labeled ABY-002 has the potential to localize metastatic lesions in vivo, adds qualitative information not available today by conventional imaging techniques, and may allow the HER2 status to be determined for metastases not amenable to biopsy. To our knowledge, this is the first report on clinical imaging data obtained with a non-immunoglobulin-based scaffold protein.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Radiology, Nuclear Medicine & Medical Imaging

Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts

Maryam Oroujeni, Hanna Tano, Anzhelika Vorobyeva, Yongsheng Liu, Olga Vorontsova, Tianqi Xu, Kristina Westerlund, Anna Orlova, Vladimir Tolmachev, Amelie Eriksson Karlstrom

Summary: Combination therapy with trastuzumab and Affibody-mediated PNA-based radionuclide pretargeting significantly increased survival in mice bearing HER2-expressing xenografts, without toxicity to normal tissues.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹
Article Radiology, Nuclear Medicine & Medical Imaging

Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study

Kambiz Rahbar, Markus Essler, Kim M. Pabst, Matthias Eiber, Christian la Fouge, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Wolfgang P. Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen, Oliver Sartor

Summary: The RALU study evaluated the feasibility of using sequential a and b emitters in patients with bone-predominant metastatic castration-resistant prostate cancer. The study found that treatment with 177Lu-PSMA after 223Ra was feasible and led to a prolongation of overall survival. Few adverse events, mainly anemia and thrombocytopenia, were observed during treatment.

JOURNAL OF NUCLEAR MEDICINE (2023)

添加到收藏夹
Review Biochemistry & Molecular Biology

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer

Mei Li, Roman Zelchan, Anna Orlova

Summary: In this review, the clinical performance of FDA-approved imaging agents for prostate cancer diagnosis was evaluated, and PSMA-targeted imaging agents were found to have superior diagnostic performance in both primary and recurrent PCa.

BIOMEDICINES (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

Vladimir Tolmachev, Vitalina Bodenko, Maryam Oroujeni, Sergey Deyev, Elena Konovalova, Alexey Schulga, Sarah Lindbo, Sophia Hober, Olga Bragina, Anna Orlova, Anzhelika Vorobyeva

Summary: Non-invasive radionuclide molecular visualization of human epidermal growth factor receptor type 2 (HER2) provides stratification and response monitoring for HER2-targeting therapy. Two imaging probes, [Tc-99m]Tc-ADAPT6 and [Tc-99m]Tc-(HE)(3)-G3, demonstrate high contrast imaging and clear discrimination of high and low HER2 expression. However, [Tc-99m]Tc-ADAPT6 has better conditions for stratification sensitivity and specificity, while [Tc-99m]Tc-(HE)(3)-G3 is more suitable for monitoring early treatment response.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model

Tianqi Xu, Alexey Schulga, Elena Konovalova, Sara S. Rinne, Hongchao Zhang, Olga Vorontsova, Anna Orlova, Sergey M. Deyev, Vladimir Tolmachev, Anzhelika Vorobyeva

Summary: Pancreatic cancer (PC) is an aggressive malignancy, and targeted therapies could improve its treatment. Overexpression of HER3 and EpCAM in PC is associated with poor prognosis. The study investigated whether co-targeting HER3 with MM-121 and EpCAM with Ec1-LoPE could enhance therapeutic efficacy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹
Article Oncology

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation

Fanny Lundmark, Ayman Abouzayed, Sara S. S. Rinne, Vasiliy Timofeev, Nadezhda Sipkina, Maria Naan, Anastasia Kirichenko, Maria Vasyutina, Daria Ryzhkova, Vladimir Tolmachev, Ulrika Rosenstrom, Anna Orlova

Summary: Prostate cancer is the most diagnosed cancer and leading cause of cancer-related deaths in men. This study presents the preclinical characterization and evaluation of a radiotracer that targets both PSMA and GRPR for PET imaging of prostate cancer. The findings support the clinical translation of the radiotracer and represent a step towards its first clinical trial.

CANCERS (2023)

添加到收藏夹
Article Pharmacology & Pharmacy

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

Yongsheng Liu, Rezan Gueler, Yunqi Liao, Anzhelika Vorobyeva, Olof Widmark, Theodorus J. J. Meuleman, Anna Koijen, Leendert J. J. van den Bos, Robert Naasz, Vitalina Bodenko, Anna Orlova, Caroline Ekblad, Vladimir Tolmachev, Fredrik Y. Y. Frejd

Summary: This study explores the use of Chemo-Enzymatic Peptide Synthesis (CEPS) to produce a therapeutic HER2 targeted Affibody molecule. The resulting molecule shows thermodynamic stability, binding specificity to HER2, and extended time in circulation. CEPS proves to be a viable method for producing functional Affibody-fusion molecules.

PHARMACEUTICS (2022)

添加到收藏夹
Article Oncology

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Yongsheng Liu, Tianqi Xu, Anzhelika Vorobyeva, Annika Loftenius, Vitalina Bodenko, Anna Orlova, Fredrik Y. Frejd, Vladimir Tolmachev

Summary: Affibody molecules are artificial proteins that can target cancer-related molecular abnormalities. Clinical studies have shown that they can be used for radionuclide diagnostics and therapy. This study demonstrated that re-engineered Affibody molecules can increase the survival of mice with human tumors, and the combination of Affibody molecules and a monoclonal antibody was the most effective treatment.

CANCERS (2023)

添加到收藏夹
Article Oncology

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer

Olga Bragina, Vladimir Chernov, Alexey Schulga, Elena Konovalova, Sophia Hober, Sergey Deyev, Jens Sorensen, Vladimir Tolmachev

Summary: The overexpression of HER2 receptor in certain breast cancers can be successfully treated with trastuzumab and pertuzumab antibodies. Radionuclide imaging can assist in selecting patients for antibody treatment. The small-sized radiolabelled scaffold proteins ADAPT6 and DARPin have shown excellent imaging properties and promising results in the imaging of HER2 in preclinical and Phase I clinical trials.

CANCERS (2023)

添加到收藏夹
Article Medicine, General & Internal

The GRPR Antagonist [Tc-99m]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Ayman Abouzayed, Jesper Borin, Fanny Lundmark, Anastasiya Rybina, Sophia Hober, Roman Zelchan, Vladimir Tolmachev, Vladimir Chernov, Anna Orlova

Summary: A kit was successfully prepared for prospective use in an early-phase clinical study, allowing for one-pot single-step radiolabeling with technetium-99m. The radiolabeled peptide maintained its binding properties and showed good safety in animal models after 18 months of storage. Therefore, the prepared kit can be further evaluated for clinical application.

DIAGNOSTICS (2023)

添加到收藏夹
Article Biochemistry & Molecular Biology

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Ayman Abouzayed, Panagiotis Kanellopoulos, Alisa Gorislav, Vladimir Tolmachev, Theodosia Maina, Berthold A. Nock, Anna Orlova

Summary: This study presents a new GRPR antagonist with improved stability and specificity for the theranostics of prostate cancer. In vitro and in vivo experiments showed that the new compound demonstrated higher stability and selective targeting, indicating its potential therapeutic value.

BIOMOLECULES (2023)

添加到收藏夹
Article Medicine, General & Internal

A direct comparison of the diagnostic efficacy of alternative scaffold- based radiopharmaceuticals [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in patients with HER2-positive breast cancer

O. D. Bragina, S. M. Deyev, E. Yu Garbukov, V. E. Goldberg, V. I. Chernov, V. M. Tolmachev

Summary: This study compared the diagnostic efficacy of two diagnostic agents, [(99)mTc]Tc-ADAPT6 and [(99)mTc]Tc-(HE)3-G3, in HER2-positive breast cancer patients. The results showed that [(99)mTc]Tc-ADAPT6 had higher accumulation values, making it a more promising diagnostic agent.

BYULLETEN SIBIRSKOY MEDITSINY (2023)

添加到收藏夹
暂无数据
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.